Is Thymosin Alpha-1 Legal in Florida?

HealthRX.com

No FDA approval, and no Florida rule is stated on this page

Print or save as PDF

  • FDA approval / None; no US marketing application exists [1]
  • State-licensed pharmacies and physicians / In none of the three interim-policy categories, list updated May 14, 2026 [2]
  • Outsourcing facilities / Category 3, nominated without adequate support [4]
  • Safety-risk table / Nominated but withdrawn; FDA's immunogenicity concerns remain posted [5]
  • Advisory committee vote / 4 yes, 17 no, December 4, 2024 [3]
  • Approved in / Italy, India, Hong Kong (Zadaxin) [1]

The short answer

Thymosin alpha-1 (thymalfasin) has no US marketing approval: a Drugs@FDA search found no application for it, and its four US orphan drug designations are a separate process, not an approval [1]. Zadaxin, the finished 1.6 mg injection sold outside the US, is not interchangeable with bulk peptide powder [1].

What the federal compounding rules say

FDA says state-licensed pharmacies and physicians may compound only with bulk substances that meet a USP or NF monograph, are components of FDA-approved drugs, or appear on FDA's list of bulk substances that can be used in compounding [6]. Thymosin alpha-1 has no FDA-approved product in the US [1], and FDA has proposed not adding it to the bulk-substances list [3].

FDA's interim policy places nominated substances in three categories. FDA says it does not intend to act against compounders using category 1 substances when the guidance conditions are met [6]. Thymosin alpha-1 is in none of the three categories on the list for state-licensed pharmacies and physicians, updated May 14, 2026, so the category 1 policy does not apply to it [2]. On the separate list for outsourcing facilities, updated March 21, 2025, it is in category 3, nominated without adequate support [4].

The safety-risk listing and the advisory committee vote

FDA's page on bulk substances that may present significant safety risks lists thymosin alpha-1 in the nominated-but-withdrawn table: it had been in category 2 and came off because the nominators withdrew [5]. FDA's concerns are still posted there, including significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information inadequate for the agency to understand the extent of any safety issues [5].

On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate. Members who voted no cited no compelling evidence of clinical effectiveness and safety [3]. Thymosin alpha-1 is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [7].

Where thymosin alpha-1 is approved

FDA's December 2024 review lists authorizations in Italy, where Zadaxin is an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1]. Two reviews by authors tied to the Zadaxin developer put the number of approving countries at more than 30 in 2007 and over 35 in 2009 [8][9]. A foreign approval is not a US approval.

Does Florida law add anything?

The federal records above describe FDA and HHS status only. They do not address Florida state law, and this page does not state a Florida-specific legal status for thymosin alpha-1.

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. What does the article say about thymosin alpha-1's four US orphan drug designations?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Questions worth asking

Choose the questions you want to keep

Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application for it, and its four orphan drug designations are a separate process, not an approval [1]. Zadaxin is authorized in Italy, India and Hong Kong [1].
Can a US compounding pharmacy prepare thymosin alpha-1?
It appears in none of the three interim-policy categories for state-licensed pharmacies and physicians [2], and in category 3 on the outsourcing-facility list [4]. FDA has proposed not adding it to the bulk-substances list [3].
Has FDA flagged thymosin alpha-1 as a safety risk?
It is in the nominated-but-withdrawn table on FDA's safety-risk page; it had been in category 2 and came off because the nominators withdrew [5]. FDA's concerns about immunogenicity for certain routes, peptide impurities and inadequate safety information remain posted [5].
Is thymosin alpha-1 banned in sport?
It is not named on WADA's 2026 Prohibited List [10]. WADA does name thymosin-beta-4 and its derivatives such as TB-500, which is a different peptide [10].
Show all 10 referencesHide references
  1. U.S. Food and Drug Administration. FDA review of thymosin alpha-1 (December 2024). FDA document 183820
  2. U.S. Food and Drug Administration. List of bulk drug substances for state-licensed pharmacies and physicians (interim policy categories). FDA document 94155
  3. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee, December 4, 2024. FDA document 185642
  4. U.S. Food and Drug Administration. List of bulk drug substances for outsourcing facilities (interim policy categories). FDA document 94164
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  6. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA.
  7. U.S. Department of Health and Human Services. Peptide enforcement discretion policy, Appendix B. HHS policy appendix
  8. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
  9. Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
  10. World Anti-Doping Agency. 2026 Prohibited List. WADA 2026 Prohibited List
Evidence overview for Is Thymosin Alpha-1 Legal in Florida?